


We Claim:

- 5 1. A compound of the formula:



Formula I


wherein,

10

Y represents CH₂ or O;

R1 and R2 each independently represent hydrogen or fluoro

R3 represents a group of the formula:




15

wherein Z represents (CH₂)_n or -CR₄R₅-CH₂-;

n represents 0-3; and

Het represents a group of the formula:




-71-

R4 and R5 each independently represent at each occurrence hydrogen or methyl;

R6 and R7 each independently represent at each occurrence hydrogen, methyl, or ethyl;

5 provided Formula I does not represent a compound selected from the group consisting of

-72-



or a pharmaceutically acceptable salt thereof.


2. The compound according to Claim 1 wherein R¹ represents hydrogen.

-73-

3. The compound according to Claim 1 wherein R¹ represents fluoro.
4. The compound according to any one of Claims 1-3 wherein R² represents hydrogen.

5. The compound according to any one of Claims 1-3 wherein R² represents fluoro.



6. The compound according to any one of Claims 1-5 wherein R³ represents a group of the formula:




wherein Z represents (CH₂)_n or -CR₄R₅-CH₂-;

n represents 0-3; and

Het represents a group of the formula:




7. The compound according to Claim 6 wherein Het represents a group of the formula:




8. The compound according to Claim 6 wherein Het represents a group of the formula:


-74-



9. The compound according to any one of Claims 1-6 wherein R³ represents
5 a group of the formula:




10. The compound according to Claim 9 wherein R³ represents a group of the
formula:




10

11. The compound according to Claim 9 wherein R³ represents a group of the
formula:

-75-




12. The compound according to any one of Claims 1-5 wherein R^3 represents a group of the formula:



5

13. The compound according to Claim 12 wherein R^3 represents a group of the formula:



10

14. A pharmaceutical composition comprising the compound according to any one of Claims 1-13 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.

15

15. A method of treating a disorder selected from the group consisting of Conn's Syndrome, primary and secondary hyperaldosteronism, increased sodium retention, increased magnesium and potassium excretion (diuresis), increased water retention, hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with

excess catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle weakness, increased melanin pigmentation of the skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus, polyartitis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar disorder, anxiety disorders, and personality disorders, comprising administering to a patient in need thereof a compound as claimed in any one of Claims 1-13, or a pharmaceutically acceptable salt thereof.

16. The method according to Claim 15 wherein the disorder is selected from the group consisting of is diastolic or systolic congestive heart failure, inflammation,

rheumatoid arthritis, an autoimmune disorder, asthma, or chronic obstructive pulmonary disease.

17. The method according to Claim 16 wherein the disorder is diastolic or
5 systolic congestive heart failure, inflammation, or rheumatoid arthritis.

18. The use of a compound according to any one of Claims 1-13, or
apharmaceutically acceptable salt thereof, as an agent for the treatment of Conn's
Syndrome, primary and secondary hyperaldosteronism, increased sodium retention,
10 increased magnesium and potassium excretion (diuresis), increased water retention,
hypertension (isolated systolic and combined systolic/diastolic), arrhythmias, myocardial
fibrosis, myocardial infarction, Bartter's Syndrome, disorders associated with excess
catecholamine levels, diastolic and systolic congestive heart failure (CHF), peripheral
vascular disease, diabetic nephropathy, cirrhosis with edema and ascites, esophageal
15 varices, Addison's Disease, muscle weakness, increased melanin pigmentation of the
skin, weight loss, hypotension, hypoglycemia, Cushing's Syndrome, obesity,
hypertension, glucose intolerance, hyperglycemia, diabetes mellitus, osteoporosis,
polyuria, polydipsia, inflammation, autoimmune disorders, tissue rejection associated
with organ transplant, malignancies such as leukemias and lymphomas, acute adrenal
20 insufficiency, congenital adrenal hyperplasia, rheumatic fever, polyarteritis nodosa,
granulomatous polyarteritis, inhibition of myeloid cell lines, immune
proliferation/apoptosis, HPA axis suppression and regulation, hypercortisolemia,
modulation of the Th1/Th2 cytokine balance, chronic kidney disease, stroke and spinal
cord injury, hypercalcemia, hyperglycemia, acute adrenal insufficiency, chronic primary
25 adrenal insufficiency, secondary adrenal insufficiency, congenital adrenal hyperplasia,
cerebral edema, thrombocytopenia, and Little's syndrome, systemic inflammation,
inflammatory bowel disease, systemic lupus erythematosus, discoid lupus erythematosus,
polyarthritis nodosa, Wegener's granulomatosis, giant cell arthritis, rheumatoid arthritis,
osteoarthritis, hay fever, allergic rhinitis, contact dermatitis, atopic dermatitis, exfoliative
30 dermatitis, urticaria, angioneurotic edema, chronic obstructive pulmonary disease,
asthma, tendonitis, bursitis, Crohn's disease, ulcerative colitis, autoimmune chronic active
hepatitis, hepatitis, cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis,
inflamed cysts, pyoderma gangrenosum, pemphigus vulgaris, bullous pemphigoid,
dermatomyositis, eosinophilic fasciitis, relapsing polychondritis, inflammatory vasculitis,
35 sarcoidosis, Sweet's disease, type 1 reactive leprosy, capillary hemangiomas, lichen
planus, erythema nodosum, acne, hirsutism, toxic epidermal necrolysis, erythema,
multiform, cutaneous T-cell lymphoma, psychoses, cognitive disorders, memory

disturbances, mood disorders, depression, bipolar disorder, anxiety disorders, or personality disorder.

19. The use of a compound according to any one of Claims 1-13 for the
5 manufacture of a medicament for the treatment of Conn's Syndrome, primary and
secondary hyperaldosteronism, increased sodium retention, increased magnesium and
potassium excretion (diuresis), increased water retention, hypertension (isolated systolic
and combined systolic/diastolic), arrhythmias, myocardial fibrosis, myocardial infarction,
Bartter's Syndrome, disorders associated with excess catecholamine levels, diastolic and
10 systolic congestive heart failure (CHF), peripheral vascular disease, diabetic nephropathy,
cirrhosis with edema and ascites, esophageal varicies, Addison's Disease, muscle
weakness, increased melanin pigmentation of the skin, weight loss, hypotension,
hypoglycemia, Cushing's Syndrome, obesity, hypertension, glucose intolerance,
hyperglycemia, diabetes mellitus, osteoporosis, polyuria, polydipsia, inflammation,
15 autoimmune disorders, tissue rejection associated with organ transplant, malignancies
such as leukemias and lymphomas, acute adrenal insufficiency, congenital adrenal
hyperplasia, rheumatic fever, polyarteritis nodosa, granulomatous polyarteritis, inhibition
of myeloid cell lines, immune proliferation/apoptosis, HPA axis suppression and
regulation, hypercortisolemia, modulation of the Th1/Th2 cytokine balance, chronic
20 kidney disease, stroke and spinal cord injury, hypercalcemia, hyperglycemia, acute
adrenal insufficiency, chronic primary adrenal insufficiency, secondary adrenal
insufficiency, congenital adrenal hyperplasia, cerebral edema, thrombocytopenia, and
Little's syndrome, systemic inflammation, inflammatory bowel disease, systemic lupus
erythematosus, discoid lupus erythematosus, polyarthritis nodosa, Wegener's
25 granulomatosis, giant cell arthritis, rheumatoid arthritis, osteoarthritis, hay fever, allergic
rhinitis, contact dermatitis, atopic dermatitis, exfoliative dermatitis, urticaria,
angioneurotic edema, chronic obstructive pulmonary disease, asthma, tendonitis, bursitis,
Crohn's disease, ulcerative colitis, autoimmune chronic active hepatitis, hepatitis,
cirrhosis, inflammatory scalp alopecia, panniculitis, psoriasis, inflamed cysts, pyoderma
30 gangrenosum, pemphigus vulgaris, bullous pemphigoid, dermatomyositis, eosinophilic
fasciitis, relapsing polychondritis, inflammatory vasculitis, sarcoidosis, Sweet's disease,
type 1 reactive leprosy, capillary hemangiomas, lichen planus, erythema nodosum, acne,
hirsutism, toxic epidermal necrolysis, erythema, multiform, cutaneous T-cell lymphoma,
psychoses, cognitive disorders, memory disturbances, mood disorders, depression, bipolar
35 disorder, anxiety disorders, or personality disorder.